Cargando…
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. a...
Autores principales: | Contreras-Gómez, María José, Martinez, José R. W., Rivas, Lina, Riquelme-Neira, Roberto, Ugalde, Juan A., Wozniak, Aniela, García, Patricia, Munita, José M., Olivares-Pacheco, Jorge, Alcalde-Rico, Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574371/ https://www.ncbi.nlm.nih.gov/pubmed/36263116 http://dx.doi.org/10.3389/fphar.2022.1007162 |
Ejemplares similares
-
Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020) -
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016) -
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two bla(KPC-2)
gene copies without losing carbapenem resistance
por: García, Patricia, et al.
Publicado: (2022) -
Evaluation of Ceftolozane/Tazobactam, Ceftazidime/Avibactam and Meropenem/Vaborbactam Against Multidrug-Resistant (MDR) Pseudomonas
por: Shamsulddin, Haider, et al.
Publicado: (2021) -
Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
por: Gangcuangco, Louie Mar, et al.
Publicado: (2016)